Prevalence and Factors of the Performed or Scheduled COVID-19 Vaccination in a Chinese Adult General Population in Hong Kong.
COVID-19 vaccination
China
general population
perceptions
personal situation
trust toward the government
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
02 Aug 2021
02 Aug 2021
Historique:
received:
02
07
2021
revised:
27
07
2021
accepted:
30
07
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
Globally, COVID-19 vaccination programs have been rolled out. To inform health promotion, this study investigated the prevalence and associated factors of performance or being scheduled to perform at least one dose of COVID-19 vaccination (PSCV) in a Chinese adult general population. An anonymous, random telephone survey interviewed 500 adults aged 18-75 in Hong Kong, China from 14-27 May 2021. The prevalence of PSCV was 21.0%, which was significantly lower among females and those aged ≤30. Positively associated factors of PSCV included perceived protection effect of vaccination, self-perceived physical fitness for vaccination, compulsory COVID-19 testing experience, perceived need to travel, general trust toward the government, and trust toward the governmental vaccination program, while negatively associated factors included perceived low efficacy of vaccination, concerns about side effects, and chronic disease status. Furthermore, the association between sex and PSCV was fully mediated by stronger concern about side effects and lower levels of self-perceived physical fitness for COVID-19 vaccination among females than males. Moderately low prevalence of COVID-19 vaccination was observed in Hong Kong, where there was no shortage of vaccine supply. To achieve herd immunity, health promotion is greatly warranted and may incorporate messages based on the findings of this study.
Sections du résumé
BACKGROUND
BACKGROUND
Globally, COVID-19 vaccination programs have been rolled out. To inform health promotion, this study investigated the prevalence and associated factors of performance or being scheduled to perform at least one dose of COVID-19 vaccination (PSCV) in a Chinese adult general population.
METHODS
METHODS
An anonymous, random telephone survey interviewed 500 adults aged 18-75 in Hong Kong, China from 14-27 May 2021.
RESULTS
RESULTS
The prevalence of PSCV was 21.0%, which was significantly lower among females and those aged ≤30. Positively associated factors of PSCV included perceived protection effect of vaccination, self-perceived physical fitness for vaccination, compulsory COVID-19 testing experience, perceived need to travel, general trust toward the government, and trust toward the governmental vaccination program, while negatively associated factors included perceived low efficacy of vaccination, concerns about side effects, and chronic disease status. Furthermore, the association between sex and PSCV was fully mediated by stronger concern about side effects and lower levels of self-perceived physical fitness for COVID-19 vaccination among females than males.
CONCLUSION
CONCLUSIONS
Moderately low prevalence of COVID-19 vaccination was observed in Hong Kong, where there was no shortage of vaccine supply. To achieve herd immunity, health promotion is greatly warranted and may incorporate messages based on the findings of this study.
Identifiants
pubmed: 34451972
pii: vaccines9080847
doi: 10.3390/vaccines9080847
pmc: PMC8402378
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Internal funding of the Center for Health Behaviours Research, The Chinese University of Hong Kong
ID : N.A.
Références
Int J Health Policy Manag. 2021 Jan 18;:
pubmed: 33619928
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017
pubmed: 32553130
Gastroenterology. 2021 Sep;161(3):827-836
pubmed: 34048782
Soc Sci Med. 2020 Nov;265:113414
pubmed: 33038683
J Pers Soc Psychol. 1986 Dec;51(6):1173-82
pubmed: 3806354
J Infect Public Health. 2017 Sep - Oct;10(5):644-648
pubmed: 28545902
Soc Psychiatry Psychiatr Epidemiol. 2017 May;52(5):525-536
pubmed: 28258334
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067682
J Public Health (Oxf). 2005 Mar;27(1):74-9
pubmed: 15637107
J Hosp Infect. 2021 Feb;108:168-173
pubmed: 33259883
Vaccine. 2021 Feb 12;39(7):1148-1156
pubmed: 33461834
Hum Vaccin Immunother. 2021 Jun 17;:1-11
pubmed: 34137670
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720958532
pubmed: 32930035
Psychol Med. 2020 Dec 11;:1-15
pubmed: 33305716
BMC Public Health. 2016 Feb 17;16:163
pubmed: 26887323
Age Ageing. 2021 Feb 26;50(2):279-283
pubmed: 33320183
Vaccine. 2020 Oct 21;38(45):7049-7056
pubmed: 32980199
Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214
pubmed: 32730103
Nurse Educ Today. 2021 Sep;104:105010
pubmed: 34126322
Hum Vaccin Immunother. 2021 Jun 7;:1-7
pubmed: 34096836
Pharm Pract (Granada). 2021 Jan-Mar;19(1):2317
pubmed: 33828623
EClinicalMedicine. 2020 Sep;26:100495
pubmed: 32838242
Vaccines (Basel). 2021 Mar 22;9(3):
pubmed: 33810131
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
J Occup Environ Med. 2021 Jun 16;:
pubmed: 34138823
Brain Behav Immun Health. 2021 Aug;15:100277
pubmed: 34036287
Elife. 2021 May 27;10:
pubmed: 34042047
Hum Vaccin Immunother. 2021 Sep 2;17(9):2894-2902
pubmed: 33877955
Vaccines (Basel). 2020 Aug 27;8(3):
pubmed: 32867224
J Community Health. 2021 Apr;46(2):270-277
pubmed: 33389421
J Womens Health (Larchmt). 2012 Jun;21(6):666-73
pubmed: 22313026
Vaccines (Basel). 2021 Apr 21;9(5):
pubmed: 33919254
Appl Res Qual Life. 2021 Feb 5;:1-20
pubmed: 33564341
Vaccine. 2013 Oct 1;31(42):4860-6
pubmed: 23954379
Int J Semiot Law. 2020 Jul 3;:1-20
pubmed: 33214736
BMC Public Health. 2021 Jul 21;21(1):1438
pubmed: 34289817
Int J Health Policy Manag. 2020 Oct 18;:
pubmed: 33105967